Evidence map›Paper›PMID 28240519›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2017

Triple Negative Breast Cancer at the University Hospital Mohammed VI – Oujda

o Al jarroudi, n Abda, Sa Brahmi, S Afqir

Abstract read
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

o Al jarroudiService of Medical Oncology, University Hospital Mohammed VI-Oujda, Mohammed Premier University, Morocco. Email: aljarroudi.ouissam@gmail.com
n Abda
Sa Brahmi
S Afqir
Mohamed I University · MA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The triple-negative breast cancer (TNBC), defined by the absence of receptors to oestrogen and progesterone and no histochemical expression of human epidermal receptor -2, is associated with a particularly aggressive behavior. The aim of our study was to determine the clinico-pathological, therapeutic and prognostic features associated with this type of breast cancer in Morocco. Methods: A cohort retrospective study, spread over 3 years, was conducted of 116 breast cancer patients, diagnosed between January 2009 and December 2011 at the Regional Center of Oncology. Epidemiological, clinical, histological and therapeutic data were analyzed. Survival curves at 3 years were estimated by Kaplan-Meier analysis with use of the log-rank test. Results: The proportion of triple-negative breast cancer in our series was 13.2%. The average age was 46.5 years and 20,7% had a previous history of familial breast cancer. Some 56,9% of tumors were greater than 3 cm in diameter. infiltrating ductal carcinoma being the histological type in the majority of cases (75.9%). TNBC was most often associated with a high grade, grade III accounting for 50.9%. Vascular invasion was found in 58.6% of cases. Regarding lymph node involvement, 42.2% had positive lymph nodes and 15.5% featured distant metastases. Neoadjuvant chemotherapy was administrated to 20% of patients with a 23.5% complete pathologic response. The rates for overall survival and disease-free-survival at 3 years for localized stages were 70 and 55.6%, respectively. With metastatic lesions, the figures were 27.5% and 10.3% respectively. Conclusion: The TNBC is correlated with a poor prognosis with a high mortality and early relapse requiring identification of new target therapies and markers for prediction of tumoral response to various treatments.

Indexed as

negative- breast cancerprognosissurvival outcomesTriple

Identifiers

PMID28240519
PMCPMC5563100
OpenAlexW2585088553

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.